Africa Anticancer Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Radiopharmaceu

The Africa anticancer drugs market is expected to reach US$ 3.23 billion by 2031 from US$ 1.81 billion in 2024. The market is estimated to grow with a CAGR of 8.8% from 2025 to 2031.

The Africa anticancer drugs market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The increasing incidence of cancer and surging initiatives to improve cancer awareness are the key factors propelling the Africa anticancer drugs market growth.

Artificial Intelligence Accelerating Cancer Care

Artificial Intelligence (AI) is emerging as a transformative force in the anticancer drugs market, addressing critical challenges associated with genetic diversity, scarce clinical data, and limited access to personalized treatments. Amid the vast increase in cancer cases across the continent, AI is accelerating drug discovery, optimizing treatments, and fostering local innovation. The practical application of AI in cancer screening, diagnosis, and care opens the door for early cancer identification and accelerates the development of new treatment plans tailored to each patient.

Project Africa GRADIENT, a collaboration between the University of Cape Town, GlaxoSmithKline, Novartis, and the South African Medical Research Council, exemplifies AI's role in tailoring drugs to African genetic profiles. This initiative aims to enhance the efficacy of treatments designed for African populations by considering genetic variations that influence drug responses. This approach ensures that therapies are more effective and have fewer side effects, significantly improving patient outcomes. Additionally, AI accelerates the drug discovery process by analyzing vast amounts of biological data to identify potential drug candidates. Companies such as Insilico Medicine employ AI-driven platforms to design small-molecule treatments and discover drug targets, reducing drug development timelines from years to months. This rapid development is crucial for addressing the increasing cancer burden in Africa, where early detection and treatment options are often limited. In April 2023, AstraZeneca (a global pharmaceutical company) joined forces with South African health-tech firm MedSol AI Solutions to advance the use of AI in breast cancer detection. Their collaboration centers around a cutting-edge Wi-Fi-enabled ultrasound probe capable of identifying breast cancer within seconds. Their Melusi Breast AI rapid detection app will be deployed in rural clinics to support early diagnosis, particularly in underserved areas. A dedicated referral system backs the initiative to ensure that women with positive results can access timely therapeutic interventions. Thus, AI integration into the cancer care landscape in Africa would enhance treatment outcomes and promote self-reliance in medical research and development. By harnessing AI, African nations can address the unique challenges posed by genetic diversity and limited access to personalized care, paving the way for more equitable healthcare solutions. Hence, by enabling personalized treatments, accelerating drug development, and fostering inclusive research, AI is setting new trends in the Africa anticancer drugs market.

Based on drug class, the Africa anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, hormonal drugs, immunotherapy drugs, gene therapy drugs, radiopharmaceuticals, and others. The cytotoxic drugs segment held the largest share in 2024. The targeted drugs segment is expected to register the highest CAGR during 2025–2031.
Based on indication, the Africa anticancer drugs market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and others. The lung cancer segment held the largest market share in 2024, and the breast cancer segment is estimated to register the highest CAGR in the market during 2025–2031.
In terms of therapy type, the Africa anticancer drugs market is categorized into chemotherapy, targeted therapy, immunotherapy, gene therapy, radiopharmaceutical therapy, and others. The chemotherapy segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025–2031.
Based on dosage form, the Africa anticancer drugs market is categorized into tablet and capsule, injectable, and liquid. The tablet and capsule segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025–2031.
By sector, the market is bifurcated into public and private. The public segment held a larger share of the market in 2024. The private segment is estimated to register a higher CAGR during 2025–2031.

A few of the major primary and secondary sources referred to while preparing the report on the Africa anticancer drugs market are the GLOBOCAN – IARC, WHO Cancer Country Profiles, WHO Global Health Observatory, UN Comtrade Database, IAEA DIRAC, World Bank, WHO Global Health Expenditure Database, Ministries of Health (e.g., Egypt CAPA, Nigeria NHIS), African Medicines Agency (AMA), BMI Fitch).

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Africa anticancer drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Africa anticancer drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Africa anticancer drugs market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.